Bob Allison Ataxia Research Center Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2009
NCT00992771
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2009

Timeline

NOW
  • Now

Alternative names

Bob Allison Ataxia Research Center (BAARC)

Active Ingredients

Drugs in Phase 2 Trials (1)

varenicline (chantix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ataxia (Phase 2)

Cerebellar Ataxia (Phase 2)

Machado-Joseph Disease (Phase 2)

Spinocerebellar Ataxias (Phase 2)

Spinocerebellar Degenerations (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1